Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02504268 · ClinicalTrials.gov registry record · Phase 3
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 994
- Enrollment target
NCT02504268: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT02504268 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 994 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02504268, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 994 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if abatacept is effective in the treatment of early rheumatoid arthritis.
Primary Outcome
Simple Disease Activity Index (SDAI) is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP (TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL) SDAI Remission is defined as SDAI \<= 3.3. Using a logistic regression model that includes treatment arm, randomization s
Interventions
- DRUG Abatacept
- DRUG Methotrexate
- OTHER Abatacept Placebo
- OTHER Methotrexate Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 994 participants |
| Start Date | 2015-09-03 |
| Est. Completion | 2020-03-19 |
| Phase | Phase 3 |
What the finished NCT02504268 record still lists
NCT02504268 is an interventional study that assigns participants to a tested intervention. The registered 994 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% higher).
The record links to 0 conditions, and to 4 interventions - of which Abatacept is the first listed.
NCT02504268 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02504268 about?
NCT02504268 is a clinical study titled "Effects of Abatacept in Patients With Early Rheumatoid Arthritis". The purpose of this study is to determine if abatacept is effective in the treatment of early rheumatoid arthritis.
What is the current status of trial NCT02504268?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 994 participants. The study started on 2015-09-03. Estimated completion is 2020-03-19.
What interventions are being tested in trial NCT02504268?
The interventions under investigation include: Abatacept (DRUG), Methotrexate (DRUG), Abatacept Placebo (OTHER), Methotrexate Placebo (OTHER).
Who is sponsoring clinical trial NCT02504268?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02504268's enrollment target sits among peer trials
994 313th of 2000 higher than 1,687 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05437575 · 994 participants · Phase 3
Prehospital Analgesia INtervention Trial (PAIN)
- NCT06671704 · 994 participants · NA
GC-PRO Intervention
- NCT07005024 · 996 participants · Phase 3
DOAC - Dosing Options in AntiCoagulation Prophylaxis
- NCT05987241 · 992 participants · Phase 2
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI